Skandinaviska Enskilda Banken (SEB)’s Acadia Pharmaceuticals ACAD Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-60,514	Closed	-$1.89M	–	784
2023 Q4	$1.89M	Hold	60,514	–	–	0.01%	595
2023 Q3	$1.26M	Hold	60,514	–	–	0.01%	642
2023 Q2	$1.45M	Hold	60,514	–	–	0.01%	630
2023 Q1	$1.14M	Sell	60,514 -2,956	-5%	-$56.3K	0.01%	676
2022 Q4	$1.01M	Sell	63,470 -3,677	-5%	-$57.5K	0.01%	665
2022 Q3	$1.1M	Hold	67,147	–	–	0.01%	659
2022 Q2	$946K	Hold	67,147	–	–	0.01%	717
2022 Q1	$1.63M	Buy	67,147 +19,690	+41%	+$476K	0.01%	662
2021 Q4	$1.12M	Sell	47,457 -43,300	-48%	-$871K	0.01%	754
2021 Q3	$1.51M	Sell	90,757 -67,600	-43%	-$1.3M	0.01%	714
2021 Q2	$3.86M	Buy	158,357 +121,835	+334%	+$2.75M	0.02%	478
2021 Q1	$942K	Buy	+36,522	New	+$1.61M	0.01%	842
2020 Q3	–	Sell	-19,600	Closed	-$950K	–	1022
2020 Q2	$950K	Buy	+19,600	New	+$941K	0.01%	730

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s ACAD Position: Q1 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 60,514 shares — an estimated $1.89M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in ACAD in Q2 2020 and held it in 13 quarters. The position peaked at $3.86M in Q2 2021. 268 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

Skandinaviska Enskilda Banken (SEB) reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 60,514 Acadia Pharmaceuticals shares in Q1 2024, an estimated $1.89M.
Skandinaviska Enskilda Banken (SEB) first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 13 quarters.
Skandinaviska Enskilda Banken (SEB)'s Acadia Pharmaceuticals position peaked at $3.86M in Q2 2021.
268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2024, filed 13 May 2024.